ITRM BREAKING NOTICE: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Iterum Therapeutics plc Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action – ITRM
17. September 2021 19:30 ET
|
The Rosen Law Firm PA
NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November...
ITRM NOTICE: ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED LAW FIRM, Encourages Iterum Therapeutics plc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ITRM
19. August 2021 14:15 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Iterum Therapeutics plc (NASDAQ: ITRM) between November...
ROSEN, A LONGSTANDING LAW FIRM, Encourages Iterum Therapeutics plc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – ITRM
11. August 2021 19:45 ET
|
The Rosen Law Firm PA
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Iterum...
Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)
31. März 2020 07:00 ET
|
Iterum Therapeutics plc
Topline results from uUTI and cUTI clinical trials to be announced in Q2 2020 Iterum Therapeutics maintaining business operations amid COVID-19 public health crisis DUBLIN, Ireland and CHICAGO,...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
12. März 2020 06:45 ET
|
Iterum Therapeutics plc
--Topline data from cUTI and uUTI pivotal trials on track to report around the end of Q1----NDAs anticipated to file with the FDA in mid-2020-- DUBLIN, Ireland and CHICAGO, March 12, 2020 ...
Iterum Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference
19. Februar 2020 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors
17. Januar 2020 06:15 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections
10. Dezember 2019 16:10 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing an oral and IV penem antibiotic...
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection
18. November 2019 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Reports Third Quarter 2019 Financial Results and Highlights
12. November 2019 16:30 ET
|
Iterum Therapeutics plc
--Phase 3 topline data from the cIAI trial expected shortly-- --cUTI and uUTI Phase 3 trials remain on track to complete enrollment around year-end and report topline data in Q1 2020-- -- NDA...